← All Iris Parent Holding CORP filings

Iris Parent Holding CORP S-1 registration statements

Registration statements, filed ahead of a public offering, with the business description and financials a first-time investor sees.

NASDAQ
LIMN
Iris Parent Holding CORP
S-1: Liminatus Pharma Launches Offering Amid Financial Strain
Liminatus Pharma, a pre-clinical stage biopharmaceutical company, is offering up to 6.9 million shares and 10.3 million warrants to fund its CD47 immune checkpoint inhibitor development, despite significant losses and Nasdaq compliance issues.
NASDAQ
LIMN
Iris Parent Holding CORP
S-1/A: Liminatus Pharma Completes SPAC Merger, Faces Funding Challenges
Liminatus Pharma, a pre-clinical stage biotech, completed its business combination with Iris Acquisition Corp., securing initial funding but still faces significant capital needs and a going concern warning.
NASDAQ
LIMN
Iris Parent Holding CORP
S-1: Liminatus Pharma Goes Public via SPAC Merger, Faces Significant Financial Hurdles Despite Promising Cancer Therapy
Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, has completed its business combination with Iris Acquisition Corp., listing on Nasdaq, but faces substantial doubt about its ability to continue as a going concern due to a history of significant losses and limited cash reserves.